Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074667 | 1.00 | GRIK1 (0.50) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| SCHEMBL10513370 | 1.00 | GRIK1 (0.50) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| Hydrochloric Acid SCHEMBL21246725 | 0.98 | GRIK1 (0.48) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| SCHEMBL1172846 | 0.84 | MGAM (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL30722280 | 0.84 | MGAM (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL1172849 | 0.84 | MGAM (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL2617390 | 0.84 | MGAM (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL14456726 | 0.84 | MGAM (0.50) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| SCHEMBL25491149 | 0.84 | GRIK1 (0.48) | GRIK1GRIA4GRIK3GRIK5SLC1A1 | |
| Cyclohexylamine SCHEMBL5689389 | 0.83 | GRIK1 (0.43) | GRIK1GRIA4GRIK3GRIK5SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827584-B2 | Process for preparing cyanoacetates | HENKEL AG & CO. KGAA (DE) | 2023-11-28 | — | — | US | disclosed |
| US-11827584-B2 | Process for preparing cyanoacetates | HENKEL AG & CO. KGAA (DE) | 2023-11-28 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220033349-A1 | PROCESS FOR PREPARING CYANOACETATES | HENKEL AG & CO. KGAA (DE) | 2022-02-03 | — | — | US | disclosed |
| WO-2020212585-A1 | PROCESS FOR PREPARING CYANOACETATES | Henkel IP & Holding GmbH (DE) | 2020-10-22 | — | — | WO | disclosed |
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170172957-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-2714029-B1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-08 | — | — | US | disclosed |
| WO-2012166533-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | BIGNAN GILLES (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302621-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| EP-2318376-A1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| WO-2010017401-A1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090258079-A1 | Biocompatible Block Copolymer, Use Thereof and Manufacturing Method Thereof | TOKYO CRO, INC. (JP) | 2009-10-15 | — | — | US | disclosed |
| CN-101331173-A | Biocompatible block copolymer, use thereof, and production method thereof | TOKYO CRO INC (JP) | 2008-12-24 | — | — | CN | disclosed |
| EP-1932870-A1 | BIOCOMPATIBLE BLOCK COPOLYMER, USE THEREOF, AND PRODUCTION METHOD THEREOF | Tokyo Cro, Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | GRIK1 3052/4885GRIA4 3442/4885GRIK3 4328/4885 |
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | GOT2, GOT1, OTC | GRIK1 1732/4885GRIA4 1721/4885GRIK3 2524/4885 |
| US-20220033349-A1 | PROCESS FOR PREPARING CYANOACETATES | PCCA, DNPEP, ASNS | GRIK1 515/4885GRIA4 846/4885GRIK3 384/4885 |
| US-11827584-B2 | Process for preparing cyanoacetates | PCCA, DNPEP, ASNS | GRIK1 515/4885GRIA4 846/4885GRIK3 384/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | GRIK1 3514/4885GRIA4 3980/4885GRIK3 4586/4885 |
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | GRIK1 766/4885GRIA4 770/4885GRIK3 959/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GRIK1 2914/4885GRIA4 3341/4885GRIK3 3084/4885 |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | GOT2, GOT1, OTC | GRIK1 1732/4885GRIA4 1721/4885GRIK3 2524/4885 |
| US-20090258079-A1 | Biocompatible Block Copolymer, Use Thereof and Manufacturing Method Thereof | HCAR1, FGB, HDGF | GRIK1 2683/4885GRIA4 3003/4885GRIK3 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.